Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
NCT00745030 · Northwestern University · NA · terminated · last registry update 2024-01-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low subject recruitment and enrollment.” | – | Registry record, Northwestern University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MTNR1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-12-05Results posted on the registry: Seattle Institute for Biomedical and Clinical Research, olanzapine and melatonin (NCT00512070)
- 2024-11-22Phase 3 first posted: Vanda Pharmaceuticals, Tasimelteon + Placebo (NCT06701396)
- 2024-11-12Phase 3 first posted: Ain Shams University, Melatonin (NCT06685679)
- 2024-09-03Also stopped (withdrawn): University of Nebraska, Melatonin + Diphenhydramine (NCT03688464)
- 2024-08-23Results posted on the registry: Universitaire Ziekenhuizen KU Leuven, Antithrombin-III + Infliximab (NCT02251041)
- 2024-08-22Results posted on the registry: Northwell Health, a drug against MTNR1A (NCT05349188)
- 2024-07-22Phase 3 first posted: Nanjing Chia-tai Tianqing Pharmaceutical, Ramelteon + Ramelteon placebo (NCT06512363)
- 2024-07-19Phase 3 first posted: Sultan Qaboos University, Intervention 1 + Intervention 2 (NCT06509191)
- 2024-07-16Results posted on the registry: James A. Keeney, Diphenhydramine (Benadryl) (NCT03968939)
- 2024-07-05Results posted on the registry: Neurim Pharmaceuticals Ltd., Piromelatine + Placebo (NCT02615002)
- 2024-06-26Phase 3 first posted: Odense University Hospital, Melatonin 10 MG + Placebo (NCT06476392)
- 2024-06-06Results posted on the registry: Stony Brook University, Melatonin and Donepezil (NCT02487082)
- 2024-06-06Also stopped (terminated): Stony Brook University, Melatonin and Donepezil (NCT02487082)
- 2024-05-29Also stopped (terminated): Mayo Clinic, a drug against MTNR1A (NCT05307770)
- 2024-05-08Phase 3 first posted: Beni-Suef University, Myoinositol + Co-Enzyme Q10 (NCT06405204)
- 2024-02-07Results posted on the registry: State University of New York at Buffalo, Melatonin (NCT04474483)
- 2024-02-07Also stopped (terminated): State University of New York at Buffalo, Melatonin (NCT04474483)
- 2024-01-26Also stopped (withdrawn): University of Florida, a drug against MTNR1A (NCT03843008)
- 2023-12-19Results posted on the registry: Rush University Medical Center, a drug against MTNR1A (NCT02373189)
- 2023-11-13Results posted on the registry: Brigham and Women's Hospital, a drug against MTNR1A (NCT01863446)
- 2023-10-26Phase 3 first posted: University of Jordan, Placebo + Diazepam (NCT06103188)
- 2023-10-13Results posted on the registry: Amy Gelfand, Melatonin + Placebo oral capsule (NCT03150797)
- 2023-10-13Also stopped (terminated): Amy Gelfand, Melatonin + Placebo oral capsule (NCT03150797)
- 2023-10-02Phase 3 first posted: Lone Baandrup, Melatonin + Quetiapine (NCT06062953)
- 2023-09-15Results posted on the registry: Vanda Pharmaceuticals, Tasimelteon + Placebo (NCT03373201)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision